However, none of the ORs related to age at first use, duration of use, total number of applications, and years since first use, was statistically significant.
There were no significant differences in home oxygen use, duration of symptoms, or respiratory infection triggers between the two cohorts.
The following interaction terms were found to be significant: Age*cirrhosis, Age*COPD, Difference in SOFA day3-day1*sepsis, duration of mechanical ventilation*duration of vasopressor use, duration of mechanical ventilation*cirrhosis, duration of mechanical ventilation*tracheostomy, duration of vasopressor use*cirrhosis, duration of vasopressor use*tracheostomy, ESRD*CHF, RRT*HTN, RRT*sepsis.
Insulin use, duration of infusion, weight, potassium replacement or presence of hypokalaemia had no statistical significance relating to loss of regulation (Tables 45 and 46).
Grading scales also exist to classify the severity of mild TBI, commonly called concussion; these use duration of LOC, PTA, and other concussion symptoms.
However, age, duration of diabetes, duration of SU use, duration of insulin use, duration of combination treatment, mean HbA1c, mean fasting C-peptide, and insulin resistance parameters did not differ between the two groups.
For each period, we asked for the age at starting use, duration of use and brand name.
Correlational analyses between last stimulant use, duration of stimulant abuse, and cognitive or personality domain measures did not reach significance.
The average topical CsA use duration of the patients was 5.1 ± 3.5 months (1 13 months) (Table 1).
These analyses were also adjusted for age, BMI, sex, diabetes treatment, years of smoking, insulin use, duration of diabetes, and use of statins.
